The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 801 Mounjaro articles
With 1 in 8 American adults now taking GLP-1 medications for diabetes or weight loss, pharmacists are key allies in navigating costs, side effects, and long-term success. Experts like Martin Torres, PharmD, emphasize their role in maximizing benefits while minimizing risks. Here are three essential ways they support your GLP-1 experience.
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
Retatrutide, a promising new weight-loss injection, targets three hormone receptors to tackle obesity and diabetes head-on. Clinical trials demonstrate significant weight loss, and experts suggest it may support longevity goals too. Discover how this triple-action therapy stands out in metabolic health.
New studies uncover genetic variations in GLP1R and GIPR genes that predict better weight loss and higher side effect risks with GLP-1 drugs like Ozempic and Mounjaro. Cardiac protections from semaglutide appear separate from obesity reduction. A mouse study highlights noncoding DNA mutations' profound developmental impacts.
A large study presented in San Diego reveals semaglutide use is not associated with higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with overweight or obesity. In fact, it lowered NAION risk by 64% among those with type 2 diabetes compared to non-GLP-1 therapies. Experts emphasize continued monitoring of blood sugar and blood pressure.
It starts with an Instagram reel from an influencer hyping potent weight-loss peptides. Soon, Indians dive into YouTube explainers, Reddit threads, and chat groups, ending with unapproved shipments from China. Hundreds rely on these cheaper alternatives to pricey Mounjaro and Ozempic amid GLP-1 plateaus.
Counterfeit versions of retatrutide, a promising but unapproved weight loss drug, are flooding online markets despite ongoing phase 3 clinical trials. Experts like obesity specialist Samantha Hocking highlight its potential for 29% body weight loss by targeting GLP-1, GIP, and glucagon. However, doctors and Eli Lilly warn of serious risks from these fake products.
Eli Lilly's Foundayo, a groundbreaking once-daily oral GLP-1 pill for weight loss, is now shipping nationwide in the US following FDA approval. Backed by the ATTAIN trials, it delivered an average 27-pound loss at the highest dose. Discover access options, pricing, and what patients need to know.
New research from 23andMe reveals genetic variants in GLP1R that boost weight loss from GLP-1 drugs by up to 3.3 pounds. GIPR mutations increase vomiting risk on tirzepatide. Meanwhile, semaglutide's heart benefits appear independent of weight loss, opening doors to precision dosing.
